2018
Kahounová, Zuzana; Kurfürstová, Daniela; Bouchal, Jan; Kharaishvili, Gvantsa; Navrátil, Jiří; Remšík, Ján; Šimečková, Šárka; Študent, Vladimír; Kozubík, Alois; Souček, Karel
In: Cytometry. Part A : the journal of the International Society for Analytical Cytology, vol. 93, no. 9, pp. 941–951, 2018, ISSN: 1552-4930 1552-4922, (Place: United States).
Abstract | Links | BibTeX | Tags: anti-fibroblast, Biomarkers/*metabolism, Breast Neoplasms/metabolism, cancer-associated fibroblasts, Cell Line, Endopeptidases, Epithelial Cell Adhesion Molecule/metabolism, Epithelial Cells/metabolism, Epithelial-Mesenchymal Transition/*physiology, epithelial-to-mesenchymal transition, Female, fibroblast activation protein α, fibroblast surface protein, Fibroblasts/*metabolism, Gelatinases/*metabolism, Humans, Leukocyte Common Antigens/metabolism, Male, Membrane Proteins/*metabolism, PC-3 Cells, Platelet Endothelial Cell Adhesion Molecule-1/metabolism, Prostatic Neoplasms/metabolism, Serine Endopeptidases/*metabolism, Transforming Growth Factor beta1/metabolism, Tumor
@article{kahounova_fibroblast_2018,
title = {The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition.},
author = {Zuzana Kahounová and Daniela Kurfürstová and Jan Bouchal and Gvantsa Kharaishvili and Jiří Navrátil and Ján Remšík and Šárka Šimečková and Vladimír Študent and Alois Kozubík and Karel Souček},
doi = {10.1002/cyto.a.23101},
issn = {1552-4930 1552-4922},
year = {2018},
date = {2018-07-01},
journal = {Cytometry. Part A : the journal of the International Society for Analytical Cytology},
volume = {93},
number = {9},
pages = {941–951},
abstract = {The identification of fibroblasts and cancer-associated fibroblasts from human cancer tissue using surface markers is difficult, especially because the markers used currently are usually not expressed solely by fibroblasts, and the identification of fibroblast-specific surface molecules is still under investigation. It was aimed to compare three commercially available antibodies in the detection of different surface epitopes of fibroblasts (anti-fibroblast, fibroblast activation protein α, and fibroblast surface protein). The specificity of their expression, employing fibroblast cell lines and tumor-derived fibroblasts from breast and prostate tissues was investigated. Both the established fibroblast cell line HFF-1 and ex vivo primary fibroblasts isolated from breast and prostate cancer tissues expressed the tested surface markers to different degrees. Surprisingly, those markers were expressed also by permanent cell lines of epithelial origin, both benign and cancer-derived (breast-cell lines MCF 10A, HMLE and prostate-cell lines BPH-1, DU 145, and PC-3). The expression of fibroblast activation protein α increased on the surface of previously described models of epithelial cells undergoing epithelial-to-mesenchymal transition in response to treatment with TGF-β1. To prove the co-expression of the fibroblast markers on cells of epithelial origin, we used freshly dissociated human prostate and breast cancer tissues. The results confirmed the co-expression of anti-fibroblast and fibroblast surface protein on CD31/CD45-negative/EpCAM-positive epithelial cells. In summary, our data support the findings that the tested fibroblast markers are not fibroblast specific and may be expressed also by cells of epithelial origin (e.g., cells undergoing EMT). Therefore, the expression of these markers should be interpreted with caution, and the combination of several epitopes for both positive (anti-fibroblast or fibroblast activation protein α) and negative (EpCAM) identification of fibroblasts from breast and prostate tumor tissues is advised. © 2017 International Society for Advancement of Cytometry.},
note = {Place: United States},
keywords = {anti-fibroblast, Biomarkers/*metabolism, Breast Neoplasms/metabolism, cancer-associated fibroblasts, Cell Line, Endopeptidases, Epithelial Cell Adhesion Molecule/metabolism, Epithelial Cells/metabolism, Epithelial-Mesenchymal Transition/*physiology, epithelial-to-mesenchymal transition, Female, fibroblast activation protein α, fibroblast surface protein, Fibroblasts/*metabolism, Gelatinases/*metabolism, Humans, Leukocyte Common Antigens/metabolism, Male, Membrane Proteins/*metabolism, PC-3 Cells, Platelet Endothelial Cell Adhesion Molecule-1/metabolism, Prostatic Neoplasms/metabolism, Serine Endopeptidases/*metabolism, Transforming Growth Factor beta1/metabolism, Tumor},
pubstate = {published},
tppubtype = {article}
}
The identification of fibroblasts and cancer-associated fibroblasts from human cancer tissue using surface markers is difficult, especially because the markers used currently are usually not expressed solely by fibroblasts, and the identification of fibroblast-specific surface molecules is still under investigation. It was aimed to compare three commercially available antibodies in the detection of different surface epitopes of fibroblasts (anti-fibroblast, fibroblast activation protein α, and fibroblast surface protein). The specificity of their expression, employing fibroblast cell lines and tumor-derived fibroblasts from breast and prostate tissues was investigated. Both the established fibroblast cell line HFF-1 and ex vivo primary fibroblasts isolated from breast and prostate cancer tissues expressed the tested surface markers to different degrees. Surprisingly, those markers were expressed also by permanent cell lines of epithelial origin, both benign and cancer-derived (breast-cell lines MCF 10A, HMLE and prostate-cell lines BPH-1, DU 145, and PC-3). The expression of fibroblast activation protein α increased on the surface of previously described models of epithelial cells undergoing epithelial-to-mesenchymal transition in response to treatment with TGF-β1. To prove the co-expression of the fibroblast markers on cells of epithelial origin, we used freshly dissociated human prostate and breast cancer tissues. The results confirmed the co-expression of anti-fibroblast and fibroblast surface protein on CD31/CD45-negative/EpCAM-positive epithelial cells. In summary, our data support the findings that the tested fibroblast markers are not fibroblast specific and may be expressed also by cells of epithelial origin (e.g., cells undergoing EMT). Therefore, the expression of these markers should be interpreted with caution, and the combination of several epitopes for both positive (anti-fibroblast or fibroblast activation protein α) and negative (EpCAM) identification of fibroblasts from breast and prostate tumor tissues is advised. © 2017 International Society for Advancement of Cytometry.
2015
Slabáková, Eva; Kharaishvili, Gvantsa; Smějová, Monika; Pernicová, Zuzana; Suchánková, Tereza; Remšík, Ján; Lerch, Stanislav; Straková, Nicol; Bouchal, Jan; Král, Milan; Culig, Zoran; Kozubík, Alois; Souček, Karel
Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells. Journal Article
In: Oncotarget, vol. 6, no. 34, pp. 36156–36171, 2015, ISSN: 1949-2553, (Place: United States).
Abstract | Links | BibTeX | Tags: Animals, Breast Neoplasms/genetics/*metabolism/pathology, Cell Cycle Proteins, Cell Line, Epithelial-Mesenchymal Transition, Epithelial-Mesenchymal Transition/*physiology, Female, Heterografts, Humans, Male, MDM2/MDMX, Mice, Nuclear Proteins/*biosynthesis, Nude, Phenotype, prostate/breast cancer, Prostatic Neoplasms/genetics/*metabolism/pathology, Proto-Oncogene Proteins c-mdm2/*biosynthesis, Proto-Oncogene Proteins/*biosynthesis, Snai2/Slug, Transfection, Tumor, TWIST
@article{slabakova_opposite_2015,
title = {Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells.},
author = {Eva Slabáková and Gvantsa Kharaishvili and Monika Smějová and Zuzana Pernicová and Tereza Suchánková and Ján Remšík and Stanislav Lerch and Nicol Straková and Jan Bouchal and Milan Král and Zoran Culig and Alois Kozubík and Karel Souček},
doi = {10.18632/oncotarget.5392},
issn = {1949-2553},
year = {2015},
date = {2015-11-01},
journal = {Oncotarget},
volume = {6},
number = {34},
pages = {36156–36171},
abstract = {Plasticity of cancer cells, manifested by transitions between epithelial and mesenchymal phenotypes, represents a challenging issue in the treatment of neoplasias. Both epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are implicated in the processes of metastasis formation and acquisition of stem cell-like properties. Mouse double minute (MDM) 2 and MDMX are important players in cancer progression, as they act as regulators of p53, but their function in EMT and metastasis may be contradictory. Here, we show that the EMT phenotype in multiple cellular models and in clinical prostate and breast cancer samples is associated with a decrease in MDM2 and increase in MDMX expression. Modulation of EMT-accompanying changes in MDM2 expression in benign and transformed prostate epithelial cells influences their migration capacity and sensitivity to docetaxel. Analysis of putative mechanisms of MDM2 expression control demonstrates that in the context of defective p53 function, MDM2 expression is regulated by EMT-inducing transcription factors Slug and Twist. These results provide an alternative context-specific role of MDM2 in EMT, cell migration, metastasis, and therapy resistance.},
note = {Place: United States},
keywords = {Animals, Breast Neoplasms/genetics/*metabolism/pathology, Cell Cycle Proteins, Cell Line, Epithelial-Mesenchymal Transition, Epithelial-Mesenchymal Transition/*physiology, Female, Heterografts, Humans, Male, MDM2/MDMX, Mice, Nuclear Proteins/*biosynthesis, Nude, Phenotype, prostate/breast cancer, Prostatic Neoplasms/genetics/*metabolism/pathology, Proto-Oncogene Proteins c-mdm2/*biosynthesis, Proto-Oncogene Proteins/*biosynthesis, Snai2/Slug, Transfection, Tumor, TWIST},
pubstate = {published},
tppubtype = {article}
}
Plasticity of cancer cells, manifested by transitions between epithelial and mesenchymal phenotypes, represents a challenging issue in the treatment of neoplasias. Both epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are implicated in the processes of metastasis formation and acquisition of stem cell-like properties. Mouse double minute (MDM) 2 and MDMX are important players in cancer progression, as they act as regulators of p53, but their function in EMT and metastasis may be contradictory. Here, we show that the EMT phenotype in multiple cellular models and in clinical prostate and breast cancer samples is associated with a decrease in MDM2 and increase in MDMX expression. Modulation of EMT-accompanying changes in MDM2 expression in benign and transformed prostate epithelial cells influences their migration capacity and sensitivity to docetaxel. Analysis of putative mechanisms of MDM2 expression control demonstrates that in the context of defective p53 function, MDM2 expression is regulated by EMT-inducing transcription factors Slug and Twist. These results provide an alternative context-specific role of MDM2 in EMT, cell migration, metastasis, and therapy resistance.